DUBLIN–(BUSINESS WIRE)–The “Ophthalmology PACS (Picture Archiving and Communication System) Market by Type (Standalone, Integrated), Delivery (On-premise, Cloud), End User (Hospitals, Specialty Clinic, ASC), Region (North America (US, Canada) Europe,…
Author: Business Wire
BioAxone BioSciences’ Scientific Advisory Board Member, Mark Bear, PhD, Receives $500,000 Beckman-Argyros Vision Research Award
CAMBRIDGE, Mass.–(BUSINESS WIRE)–BioAxone Scientific Advisory Board member and MIT professor receives 2018 Beckman-Argyros Vision Research Award for breakthroughs in vision research.
UnitedHealthcare Eye Care Program Gives Children Across the Country Access to Comprehensive Eye Exams and Glasses
MINNETONKA, Minn.–(BUSINESS WIRE)–UnitedHealthcare launched a new program to help improve access to comprehensive eye exams and prescription glasses for children across the country.
SciFluor Announces Appointment of Robert Dempsey to Board of Directors
CAMBRIDGE, Mass.–(BUSINESS WIRE)–SciFluor Life Sciences today announced that Robert Dempsey, MBA, has joined the Board of Directors.
Global Ophthalmology Devices Market Analysis & Forecast to 2024 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Devices Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024” report has been added to ResearchAndMarkets.com’s offering. The report predicts the global ophthalmology devices market …
Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced topline efficacy results from a double-masked, randomized, placebo-controlled study (AR-13324-CS206; NCT03233308) designed to evaluate the effect of Rhopressa® (netarsudil ophthalmi
Global Near-infrared Spectroscopy Market 2018-2022 – Evolution of Miniature NIR Spectrometers Gaining Momentum – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Near-infrared Spectroscopy Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering. The Global Near-infrared Spectroscopy Market to grow at a CAGR of 9.16% during the period 2018-2022. Global Ne…
SeniorWell Announces Hiring of Dr. Lowell Weil, Jr.
CHICAGO–(BUSINESS WIRE)–SeniorWell, a mobile healthcare company, today announced its hiring of Dr. Lowell Weil, Jr. of Weil Foot & Ankle Institute.
iSchemaView RAPIDTM Technology Now Installed in More Than 500 Stroke Centers — up 48 Percent Since April
REDWOOD CITY, Calif.–(BUSINESS WIRE)–iSchemaView announces that the RAPID platform is in use at more than 520 stroke centers, including 17 hospitals at Baylor Scott & White Health.
Aerpio Reports Second Quarter 2018 Financial Results and Provides Business Update
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the second quarter ended June 30, 2018 and provided a business update. “We had a busy and productive second quarter at Aerpio,” commented Stephen Hoffman, M.D. Ph.D., Chief Executive Officer of Aerpio. “Our ongoing TIME-2b study, evaluating the effect of AKB-9778, our first-in-class Tie2 acti
STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
MONROVIA, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, and Dr. Maro Kariya of Shinjuku LASIK Clinic in Tokyo, today announced they have entered into a multi-year Strategic Cooperation Agreement to provide STAAR’s EVO Visian ICL™ intraocular lenses as a primary and premium option for patients seeking visual freedom from spectacles and contact lenses through refracti
Verseon Interim Report Charts Progress of Development Programs as It Submits Phase I Protocol for Precision Anticoagulant
FREMONT, Calif.–(BUSINESS WIRE)–Verseon’s drug discovery program, based on an industry-leading in silico platform, progresses four programs with multiple novel compounds.
CREW By True Rowing Revolutionizes Connected Fitness, Announces Funding from Olympic Rower
CAMBRIDGE, Mass.–(BUSINESS WIRE)–#crewbytruerowing–Following the Peloton revolution, the connected fitness world is again being upended by CREW by True Rowing with the announcement today of $5 million in seed capital to bring a connected indoor rowi…
Choroidal Neovascularization | A Drug Pipeline Analysis Report 2018 | Technavio
LONDON–(BUSINESS WIRE)–#RareDiseases–Technavio has announced their latest pipeline analysis report on the drug pipeline for choroidal neovascularization.
ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBC
MARIETTA, Ohio–(BUSINESS WIRE)–ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at the University of British Columbia
Princeton Identity Iris Technology Featured in Samsung Galaxy Note9
HAMILTON, N.J.–(BUSINESS WIRE)–#Biometrics–Princeton Identity Iris Technology Featured in Samsung Galaxy Note9. Iris recognition technology offers increased convenience and security.
STAAR Surgical Announces Closing of Common Stock Offering
MONROVIA, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced today the closing of the previously announced underwritten public offering of 1,999,850 shares of its common stock, which includes the full exercise of the underwriter’s option to purchase up to an additional 260,850 shares, at a price to the public of $39.00 per share. The gross proceeds of the offer
Omeros Corporation Reports Second Quarter 2018 Financial Results
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2018, which include: 2Q 2018 total and OMIDRIA® revenues were $1.7 million, compared to $17.2 million in 2Q 2017; the decrease was due to the significantly reduced usage of OMIDRIA by ambulatory surgery centers (ASCs) and hospitals during the period (January 1, 2018 through September 30, 2018) in which transitional pass
Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapies using its proprietary mucus-penetrating particle (MPP) technology with an initial focus on the treatment of eye diseases, today reported financial results for the second quarter ended June 30, 2018. “Since our last update we have made excellent progress,” said Mark Iwicki, Chairman and Chief Executive Officer. “We have defined our s
Kala Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today annou…